AVID BIOSERVICES INC (CDMO) Stock Overview
NASDAQ:CDMO - US05368M1062 - Common Stock
CDMO Key Statistics, Chart & Performance
The current stock price of CDMO is 12.49 USD. In the past month the price increased by 1.3%. In the past year, price increased by 85.86%.
CDMO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 374.26B | ||
| AMGN | AMGEN INC | 13.01 | 152.81B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 101.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.65B | ||
| ARGX | ARGENX SE - ADR | 77.89 | 44.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.78 | 39.97B | ||
| INSM | INSMED INC | N/A | 30.33B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.99B | ||
| BIIB | BIOGEN INC | 8.85 | 20.76B |
Related stock screener links
About CDMO
Company Profile
Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. The company is headquartered in Tustin, California and currently employs 371 full-time employees. The firm provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Company Info
AVID BIOSERVICES INC
14191 Myford Road
Tustin CALIFORNIA 92780 US
CEO: Nicholas S. Green
Employees: 371
Phone: 17145086100
AVID BIOSERVICES INC / CDMO FAQ
What is the stock price of AVID BIOSERVICES INC today?
The current stock price of CDMO is 12.49 USD. The price increased by 0.08% in the last trading session.
What is the ticker symbol for AVID BIOSERVICES INC stock?
The exchange symbol of AVID BIOSERVICES INC is CDMO and it is listed on the Nasdaq exchange.
On which exchange is CDMO stock listed?
CDMO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVID BIOSERVICES INC stock?
11 analysts have analysed CDMO and the average price target is 12.75 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 12.49. Check the AVID BIOSERVICES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVID BIOSERVICES INC worth?
AVID BIOSERVICES INC (CDMO) has a market capitalization of 801.11M USD. This makes CDMO a Small Cap stock.
How many employees does AVID BIOSERVICES INC have?
AVID BIOSERVICES INC (CDMO) currently has 371 employees.
What are the support and resistance levels for AVID BIOSERVICES INC (CDMO) stock?
AVID BIOSERVICES INC (CDMO) has a support level at 12.46 and a resistance level at 12.5. Check the full technical report for a detailed analysis of CDMO support and resistance levels.
Is AVID BIOSERVICES INC (CDMO) expected to grow?
The Revenue of AVID BIOSERVICES INC (CDMO) is expected to grow by 17.28% in the next year. Check the estimates tab for more information on the CDMO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVID BIOSERVICES INC (CDMO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CDMO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CDMO, evaluating the profitability, health, valuation and growth aspects
- AVID BIOSERVICES INC (CDMO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVID BIOSERVICES INC (CDMO) Sales and EPS estimates to see what analysts future expectations are.
- AVID BIOSERVICES INC (CDMO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVID BIOSERVICES INC (CDMO) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVID BIOSERVICES INC (CDMO) Stock Chart to make your own analysis
- AVID BIOSERVICES INC (CDMO) Latest news and press-releases to stay up to date.
Does AVID BIOSERVICES INC (CDMO) stock pay dividends?
CDMO does not pay a dividend.
When does AVID BIOSERVICES INC (CDMO) report earnings?
AVID BIOSERVICES INC (CDMO) will report earnings on 2025-04-22, after the market close.
What is the Price/Earnings (PE) ratio of AVID BIOSERVICES INC (CDMO)?
AVID BIOSERVICES INC (CDMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
CDMO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDMO. When comparing the yearly performance of all stocks, CDMO is one of the better performing stocks in the market, outperforming 91.92% of all stocks.
CDMO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDMO. CDMO has a bad profitability rating. Also its financial health evaluation is rather negative.
CDMO Financial Highlights
Over the last trailing twelve months CDMO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -1305.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47% | ||
| ROE | -339.34% | ||
| Debt/Equity | 3.58 |
CDMO Forecast & Estimates
11 analysts have analysed CDMO and the average price target is 12.75 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 12.49.
For the next year, analysts expect an EPS growth of 86.15% and a revenue growth 17.28% for CDMO